Comprehensive analysis of differentially expressed genes reveals the promotive effects of UBE2T on colorectal cancer cell proliferation

Abstract

Colorectal cancer (CRC) is one of the most common malignancies worldwide. Via analysis using The Cancer Genome Atlas database, the present study identified 1,835 genes that were differentially expressed in CRC, including 811 upregulated and 1,024 downregulated genes. Enrichment analyses using the Database for Annotation, Visualization and Integrated Discovery tool revealed that these differentially expressed genes were associated with the regulation of CRC progression by modulating multiple pathways, such as 'Cell Cycle, Mitotic', 'DNA Replication', 'Mitotic M-M/G1 phases' and 'ATM pathway'. To identify the key genes in CRC, protein-protein interaction (PPI) network analysis was performed and the hub modules in upregulated and downregulated PPI networks were identified. Ubiquitin-conjugating enzyme E2 T (UBE2T), a member of the E2 family, was identified to be a key regulator in CRC. To the best of our knowledge, the present study was the first to demonstrate that UBE2T expression was upregulated in CRC samples compared with normal tissues. Kaplan-Meier analysis revealed that higher expression levels of UBE2T were associated with worse prognosis compared with lower UBE2T expression levels in CRC. Additionally, the present study demonstrated that knockdown of UBE2T inhibited CRC cell proliferation. Flow cytometry assays revealed that UBE2T knockdown induced cell cycle arrest at G 1 phase and apoptosis in vitro. These results suggested that UBE2T may be a novel potential biomarker for CRC.

Knockdown of ubiquitin-conjugating enzyme E2T (UBE2T) suppresses lung adenocarcinoma progression via targeting fibulin-5 (FBLN5)

“…The dysregulation of UBE2T is closely related to the occurrence and development of various tumors [ 39 , 40 ]. Although a previous study has shown that UBE2T was elevated markedly in non-small cell lung cancer tissues and ranked first according to the hazard ratio in the survival analysis [ 18 ], the functional role and molecular mechanism of UBE2T in LUAD proliferation and metastasis remain unknown.…”

Ubiquitin‑conjugating enzymes as potential biomarkers and therapeutic targets for digestive system cancers (Review)

“…Therefore, UBE2S may be an emerging target for CRC treatment ( 105 ). Luo and Zhou ( 106 ) and Wu et al ( 107 ) demonstrated that UBE2T expression was elevated in CRC tissues and samples and that elevated UBE2T was associated with reduced OS time in clinical patients. It promotes the proliferation, migration and invasion of CRC cells and inhibits apoptosis.…”